John Hanna

John Hanna

Auto-generated profile, based on publicly available information

John Hanna

Department of Internal Medicine, Cleveland Clinic

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2025 in American Journal of Hematology
Verified
Journal Article
Open access
JHJohn Hanna
John Hanna
EZEmily C. Zabor
Emily C. Zabor
MAMoath Albliwi
Moath Albliwi
JEJessica El‐Asmar
Jessica El‐Asmar
DNDaniel P. Nurse
Daniel P. Nurse
MAMoaath Mustafa Ali
Moaath Mustafa Ali
Prognostication in acute myeloid leukemia (AML) relies on clinical, molecular, and cytogenetic factors. In this retrospective study, we examined the impact of different levels of cytogenetic response on overall survival (OS) and event‐free survival (EFS) in AML. Among 973 adult AML patients treated at Cleveland Clinic (5/2017–9/2023), 563 patients had baseline cytogenetic data and post‐treatment response assessment available. Based on baseline and response cytogenetic status, patients were categorized into: normal to normal (NL‐Cy to NL‐Cy, n = 221, 39%), normal or abnormal to gain (NL/Abnl‐Cy to Gain‐Cy, n = 46, 8.2%), abnormal to persistent (Abnl‐Cy to Persistent‐Cy, n = 81, 14%), abnormal to partial response (Abnl‐Cy to Partial‐Cy, n = 20, 3.6%), and abnormal to complete response (Abnl‐Cy to NL‐Cy, n = 195, 35%). Landmark analysis was used to account for post‐treatment assessments. The cohort had a median age of 62 years (interquartile range: 52–69), 256 females (45%), 90% were White, and median follow‐up of 45.8 months (range: 0.73–191.3). The median OS and hazard ratios (HRs) from multivariable regression analysis were as follows: NL‐Cy to NL‐Cy: 37 months (95% CI: 27–91), HR = reference; NL/Abnl‐Cy to Gain‐Cy: 14 months (95% CI: 8.6–30), HR = 1.5 (95% CI: 0.99–2.39); Abnl‐Cy to Persistent‐Cy: 13 months (95% CI: 12–18), HR = 1.61 (95% CI: 1.13–2.31); Abnl‐Cy to Partial‐Cy: 25 months (95% CI: 14‐NC), HR = 0.76 (95% CI: 0.39–1.49); and Abnl‐Cy to NL‐Cy: 27 months (95% CI: 19–101), HR = 1.25 (95% CI: 0.93–1.68) (p = 0.038). Achieving cytogenetic remission, complete or partial, was associated with better survival outcomes. These findings highlight the importance of monitoring cytogenetic responses to inform treatment decisions and support integrating cytogenetic response into risk‐adapted, personalized AML management strategies.

25 August 2025 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
MAMoath Albliwi
Moath Albliwi
EZEmily C. Zabor
Emily C. Zabor
JHJohn Hanna
John Hanna
JEJessica El-Asmar
Jessica El-Asmar
DNDaniel P. Nurse
Daniel P. Nurse
MAMoaath Mustafa Ali
Moaath Mustafa Ali

7 August 2026 in Annals of Medicine
Verified
Journal Article
Open access
JHJohn Hanna
John Hanna
HLHong Li
Hong Li
RBRyan Brown
Ryan Brown
ZBZain Ali Burney
Zain Ali Burney
KAKawther Abdallah
Kawther Abdallah
SMSandra Mazzoni
Sandra Mazzoni
Systemic immunoglobulin light-chain (AL) amyloidosis is a complex and life-threatening disorder caused by a clonal plasma cell population that produces unstable immunoglobulin light chains, which m...

19 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ABAmeed Bawwab
Ameed Bawwab
EZEmily C. Zabor
Emily C. Zabor
LKLana Khatib
Lana Khatib
MAMoath Albliwi
Moath Albliwi
JHJohn Hanna
John Hanna
MAMoaath Mustafa Ali
Moaath Mustafa Ali
Background: The prognostic significance of the proportion of normal metaphases detected at diagnosis in acute myeloid leukemia (AML) has not been systematically evaluated. Methods: We conducted a retrospective cohort study of 893 adult AML patients treated at Cleveland Clinic between 01/2015-09/2023 who underwent conventional cytogenetic analysis. Normal karyotype fraction (NKF) was defined as the proportion of normal metaphases among all metaphases analyzed at diagnosis. NKF was evaluated as a continuous measure and categorized using three-group (NKF = 0, 0 < NKF < 1, NKF = 1) and five-group functional classification systems. Primary outcomes included overall survival (OS), event-free survival (EFS), composite complete remission (CR/CRi), and relapse. Multivariable Cox proportional hazards and logistic regression models were adjusted for established prognostic covariates. Results: NKF demonstrated a bimodal distribution across the cohort. Patients with NKF = 1 achieved the highest CR/CRi rate (64%) and longest median OS (16 months) and EFS (11 months). In multivariable analyses, NKF = 1 was independently associated with improved OS (HR 0.77, 95%CI 0.61-0.97) and EFS (HR 0.72, 95%CI 0.58-0.90), and higher odds of achieving CR/CRi (OR 1.72, 95%CI 1.10-2.70) compared with NKF = 0. EFS was significantly associated with NKF categories in both classification systems (p <0.05). Conclusion: NKF is a novel, readily obtainable prognostic parameter derived from routine cytogenetics that independently predicts treatment response and survival in AML. External validation and prospective studies are warranted to support its use in clinical risk stratification frameworks.

12 August 2026 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Open access
ABAmeed Bawwab
Ameed Bawwab
EZEmily C. Zabor
Emily C. Zabor
LKLana Khatib
Lana Khatib
MAMoath Albliwi
Moath Albliwi
JHJohn Hanna
John Hanna
MAMoaath Mustafa Ali
Moaath Mustafa Ali